Arch Biopartners Inc (ARCH)
TSX Venture Exchange · Canada · prices in CAD · close of 19 Oct 2026
Key indicators
| Last close | CAD 0.790 |
|---|---|
| 52-week range | 0.390 – 1.450 |
| Return, 1 month / 3 months | −14.1% / −6.0% |
| Return, 1 year / 3 years | −18.6% / −29.5% |
| Trend | Below its 200-day average |
| RSI (14) | 41 |
| Volatility (1 year) | 91.9% |
| Worst drawdown (1 year) | -71.7% |
| Average daily value traded | 0.05M CAD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Arch Biopartners Inc is a clinical-stage biotechnology company based in Toronto, Canada. It develops drug candidates that target inflammation in acute and chronic conditions, with programmes aimed at protecting the kidneys and other organs during serious illness. Its work includes treatments for conditions such as acute kidney injury and sepsis, and it advances these candidates through preclinical and clinical testing. The company works with hospital and medical research settings and partners on developing its therapeutic candidates.
The shares are listed on the TSX Venture Exchange in Canada under the code ARCH, and the price on this page is in Canadian dollars (CAD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Arch Biopartners Inc (ARCH) trades on the TSX Venture Exchange in Canada. It last closed at CAD 0.790 on 19 October 2026.
Its price-based Market X-Ray is 61 out of 100 (a fair price profile), ranking 487 of 1,499 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 18.6% and over the last three months it fell 6.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on TSX Venture Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 70 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | -1.8% | ||
| From 52-week high | -45.5% | ||
| Momentum | 64 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -6.0% | ||
| 6-month return | 71.7% | ||
| 12-month return, skipping the last month | -5.2% | ||
| Stability (higher is calmer) | 38 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 91.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -71.7% | ||
| Liquidity | 81 · Strong | Trades actively. | |
| Average daily value traded | 0.05M CAD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −4.8% |
|---|---|
| 1 month | −14.1% |
| 3 months | −6.0% |
| 6 months | +71.7% |
| 1 year | −18.6% |
| 3 years | −29.5% |
| 5 years | – |
Signals
| 50-day / 200-day average | 0.955 / 0.804 |
|---|---|
| Golden / death cross (60 days) | Golden, 40 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.072 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on TSX Venture Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.